Lv1
16 积分 2024-01-23 加入
Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure
1天前
已完结
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
3个月前
已完结
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
3个月前
已完结
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
4个月前
已完结
Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
5个月前
已完结
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
5个月前
已完结
Extra Nodal Diffuse Large B Cell Lymphoma: Site Specific Survival Study
5个月前
已关闭
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
6个月前
已完结
The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
6个月前
已完结
Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer
7个月前
已完结
皖公网安备34019202002308
